Merit Medical ((MMSI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Merit Medical Systems, Inc. is conducting a US Post-Market Surveillance Study of the Surfacer® Inside-Out® Access Catheter System. This study aims to evaluate the system’s effectiveness in providing central venous access for patients with upper body venous occlusions or conditions that prevent conventional access. The study is significant as it addresses a critical need for alternative venous access solutions.
Intervention/Treatment: The intervention being tested is the Surfacer® Inside-Out® Access Catheter System, a device designed to facilitate catheter insertion into the central venous system for patients with challenging venous access issues.
Study Design: This is an observational, multi-center, single-arm study with a prospective cohort model. It aims to gather real-world data on the device’s performance in a clinical setting.
Study Timeline: The study began on September 10, 2021, and is currently recruiting participants. The last update was submitted on July 31, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.
Market Implications: This study update could positively impact Merit Medical’s stock performance by demonstrating the Surfacer System’s potential in addressing unmet clinical needs. Investors may view this as a strategic advantage, especially in a competitive market where innovative solutions are highly valued.
The study is ongoing, with further details available on the ClinicalTrials portal.